Ireland
--:--IST
Priya Life Science Clinical trial register
Trackers› Clinical trials› Chuo Ku
Clinical trial register · Japan

Clinical Trials in Chuo Ku, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Japan and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2493 matching records held by the registry are in this view. Synced 22 Oct 2026, 03:19 UTC
2493
Studies in scope
all four open statuses
1263
Recruiting now
open to new participants
349
Lead sponsors
across recruiting studies
Top sites
Sapporo 33 Nagoya 30 Yokohama 27 Fukuoka 19 Suita 19
Narrow the registerReset
Recruitment status
Phase
Site location
Sapporo33 Nagoya30 Yokohama27 Fukuoka19 Suita19
All 135 locations
Target enrolment
to

Trials with a site in Chuo Ku

15 of 2493 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Japan
Start
Recruiting
Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors
NCT07630961Metastatic Pancreatic Ductal Adenocarcinoma (PDAC), Non-small Cell Lung Cancer (NSCLC), HR+/HER2- Ductal Breast Cancer (BC), HR+/HER2- Lobular Breast Cancer (BC)
Novartis Pharmaceuticals
Phase 1
66
Chuo Ku
2026-06-23
Recruiting
Novartis Pharmaceuticals
Phase 2
323
Suita, Chuo Ku, Chuo-ku, Shinjuku Ku
2026-05-07
Recruiting
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
NCT07006727Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung, Neuroendocrine Prostate Cancer, Gastroenteropancreatic Neuroendocrine Carcinoma
Novartis Pharmaceuticals
Phase 1
116
Chuo Ku
2025-10-16
Recruiting
Novartis Pharmaceuticals
Phase 3
940
Nagoya, Sapporo, Kobe, Kamakura, Yokohama, Kumamoto, Chuo Ku, Chiba
2025-07-01
Recruiting
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
NCT06726148Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Extensive-stage Small Cell Lung Cancer
Novartis Pharmaceuticals
Phase 1/2
280
Chuo Ku
2025-04-03
Active, closed
Novartis Pharmaceuticals
Phase 2
396
Suita, Chuo Ku, Chuo-ku, Shinjuku Ku
2025-03-26
Recruiting
Novartis Pharmaceuticals
Phase 3
550
Nagoya, Sapporo, Yokohama, Sendai, Bunkyo-ku, Chuo Ku, Fuchū, Itabashi-ku
2024-05-21
Recruiting
Novartis Pharmaceuticals
Phase 3
450
Kashiwa, Sapporo, Kobe, Yokohama, Chuo Ku, Fukuoka, Fukushima, Ishikawa
2024-03-12
Active, closed
Novartis Pharmaceuticals
Phase 3
436
Nagoya, Sapporo, Yokohama, Sendai, Bunkyo Ku, Bunkyo-ku, Chuo Ku, Fuchū
2023-03-02
Active, closed
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
NCT05544929Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma, Carcinoma, Renal Cell, Carcinoma, Ovarian Epithelial
Novartis Pharmaceuticals
Phase 1
126
Chuo Ku
2022-10-26
Active, closed
Novartis Pharmaceuticals
Phase 1
137
Chuo Ku
2021-10-21
Active, closed
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
NCT04699188KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal, Cancer of Lung
Novartis Pharmaceuticals
Phase 1/2
344
Nagoya, Kashiwa, Osaka, Chuo Ku, Koto Ku
2021-02-24
Active, closed
Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.
NCT03891953Carcinoma, Non-Small-Cell Lung, Melanoma, Nasopharyngeal Carcinoma, Microsatellite Stable Colorectal Cancer
Novartis Pharmaceuticals
Phase 1
98
Chuo Ku
2019-05-07
Recruiting
Dabrafenib and/or Trametinib Rollover Study
NCT03340506Melanoma, Non Small Cell Lung Cancer, Solid Tumor, Rare Cancers
Novartis Pharmaceuticals
Phase 4
100
Kashiwa, Chuo Ku
2018-01-26
Recruiting
CAR-T Long Term Follow Up (LTFU) Study
NCT02445222Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program
Novartis Pharmaceuticals
Phase 3
1,105
Sapporo, Sendai, Chuo Ku, Fukuoka, Kyoto
2015-11-02
Rows per page Showing 1–15 of 15
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Japanese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 October 2026. https://priyalifescience.com/clinical-trials-japan/city/chuo-ku

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Japan and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,493 studies in total at the last sync on 22 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 15 of those studies with a site in Chuo Ku that also match the filters currently applied.

How many clinical trials are recruiting in Chuo Ku?

9 of the 15 studies on this page are recruiting new participants as of the 22 Oct 2026, 03:19 UTC sync. A further 0 have not yet opened recruitment, 6 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Chuo Ku), 15 studies
PhaseStudiesRecruitingShare
Phase 15233.3%
Phase 35433.3%
Phase 1/22113.3%
Phase 22113.3%
Phase 4116.7%

Most active sponsors

Lead sponsors with the most studies (Chuo Ku)
Lead sponsorStudiesRecruiting
Novartis Pharmaceuticals159
→

Other trial registries in Japan

This register lists Japan studies from ClinicalTrials.gov. Many studies in Japan are registered only in a national registry. We do not copy those records; search them directly:

  • jRCT (Japan Registry of Clinical Trials) — run by the Ministry of Health, Labour and Welfare; trials under Japan's Clinical Trials Act and other clinical research
  • UMIN-CTR — run by the University of Tokyo Hospital's UMIN Center; many academic and investigator-led studies
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.